Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

RETRACTED ARTICLE: SUMO-specific protease 6 promotes gastric cancer cell growth via deSUMOylation of FoxM1

Authors: Jiu-Gang Song, Hua-Hong Xie, Nan Li, Kai Wu, Ji-gang Qiu, Da-Ming Shen, Chun-Jin Huang

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

SUMOylation is a post-translational modification exerted various effects on the target proteins. SUMOylation is a highly dynamic and reversible process, which has been shown to play an important role in tumorigenesis. However, the roles of sentrin/SUMO-specific proteases (SENPs), which mediate the reverse process of SUMOylation, in tumorigenesis remains largely unexplored. Here, we uncover a critical role of SENP6 in promoting gastric cancer cells growth via regulating the deSUMOylation of a transcription factor forkhead box protein M1 (FoxM1). We demonstrated that the mRNA and protein levels were elevated in gastric cancer tissues. Overexpression of SENP6 promoted, while RNA interference depletion of endogenous SENP6 inhibited gastric cancer cells growth and the ability of colony formation. By using biochemical assays, we identified FoxM1 as a novel substrate of SENP6 in gastric cancer cells. Thus, our data suggest that SENP6, which is highly expressed in gastric cancer cells, regulates the transcriptional activity and stability of FoxM1 through deSUMOylation.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
3.
Muller S, Ledl A, Schmidt D. Sumo: a regulator of gene expression and genome integrity. Oncogene. 2004;23:1998–2008.CrossRefPubMed
4.
5.
Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007;8:947–56.CrossRefPubMed
6.
Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, et al. The sumo pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell. 2005;9:769–79.CrossRefPubMed
7.
Baek SH. A novel link between sumo modification and cancer metastasis. Cell Cycle. 2006;5:1492–5. Georgetown, Tex.CrossRefPubMed
8.
Mukhopadhyay D, Dasso M. Modification in reverse: the sumo proteases. Trends Biochem Sci. 2007;32:286–95.CrossRefPubMed
9.
Guo C, Henley JM. Wrestling with stress: roles of protein sumoylation and desumoylation in cell stress response. IUBMB Life. 2014;66:71–7.CrossRefPubMed
10.
Shen HJ, Zhu HY, Yang C, Ji F. Senp2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. Asian Pac J Cancer Prev. 2012;13:3583–7.CrossRefPubMed
11.
Qian J, Luo Y, Gu X, Wang X. Inhibition of senp6-induced radiosensitization of human hepatocellular carcinoma cells by blocking radiation-induced nf-kappab activation. Cancer Biother Radiopharm. 2013;28:196–200.CrossRefPubMed
12.
Mukhopadhyay D, Ayaydin F, Kolli N, Tan SH, Anan T, Kametaka A, et al. Susp1 antagonizes formation of highly sumo2/3-conjugated species. J Cell Biol. 2006;174:939–49.CrossRefPubMedPubMedCentral
13.
14.
Dou H, Huang C, Singh M, Carpenter PB, Yeh ET. Regulation of DNA repair through desumoylation and sumoylation of replication protein a complex. Mol Cell. 2010;39:333–45.CrossRefPubMedPubMedCentral
15.
16.
Rojas-Fernandez A, Plechanovova A, Hattersley N, Jaffray E, Tatham MH, Hay RT. Sumo chain-induced dimerization activates rnf4. Mol Cell. 2014;53:880–92.CrossRefPubMedPubMedCentral
17.
Wierstra I. The transcription factor foxm1 (forkhead box m1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res. 2013;118:97–398.CrossRefPubMed
18.
19.
Xu XS, Miao RC, Wan Y, Zhang LQ, Qu K, Liu C. Foxm1 as a novel therapeutic target for cancer drug therapy. Asian Pac J Cancer Prev. 2015;16:23–9.CrossRefPubMed
20.
Xu N, Wu SD, Wang H, Wang Q, Bai CX. Involvement of foxm1 in non-small cell lung cancer recurrence. Asian Pac J Cancer Prev. 2012;13:4739–43.CrossRefPubMed
21.
Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of forkhead box m1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007;67:8293–300.CrossRefPubMed
22.
Schimmel J, Eifler K, Sigurethsson JO, Cuijpers SA, Hendriks IA, Verlaan-de Vries M, et al. Uncovering sumoylation dynamics during cell-cycle progression reveals foxm1 as a key mitotic sumo target protein. Mol Cell. 2014;53:1053–66.CrossRefPubMed
23.
Zhang J, Yuan C, Wu J, Elsayed Z, Fu Z. Polo-like kinase 1-mediated phosphorylation of forkhead box protein m1b antagonizes its sumoylation and facilitates its mitotic function. J Biol Chem. 2015;290:3708–19.CrossRefPubMed
24.
McDowall MD, Scott MS, Barton GJ. Pips: human protein-protein interaction prediction database. Nucleic Acids Res. 2009;37:D651–6.CrossRefPubMed
25.
Wierstra I, Alves J. Foxm1, a typical proliferation-associated transcription factor. Biol Chem. 2007;388:1257–74.PubMed
26.
Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of foxm1 transcription factor: lessons from transgenic mouse models. Cell cycle. 2011;10:396–405. Georgetown, Tex.CrossRefPubMedPubMedCentral
27.
Le Lay J, Kaestner KH. The fox genes in the liver: from organogenesis to functional integration. Physiol Rev. 2010;90:1–22.CrossRefPubMed
28.
Chen W, Yuan K, Tao ZZ, Xiao BK. Deletion of forkhead box m1 transcription factor reduces malignancy in laryngeal squamous carcinoma cells. Asian Pac J Cancer Prev. 2011;12:1785–8.PubMed
29.
Metadata
Title
RETRACTED ARTICLE: SUMO-specific protease 6 promotes gastric cancer cell growth via deSUMOylation of FoxM1
Authors
Jiu-Gang Song
Hua-Hong Xie
Nan Li
Kai Wu
Ji-gang Qiu
Da-Ming Shen
Chun-Jin Huang
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3737-z

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Review

N-Methyl-N-nitrosourea as a mammary carcinogenic agent

Research Article

Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach

Research Article

Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma

Research Article

RETRACTED ARTICLE: MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma

Research Article

High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia

Research Article

Correlation between serum levels of vascular endothelial growth factor-C and sentinel lymph node status in early breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits